Gastrointestinal Cancer Articles

Experts Dissect Key Findings for  Progressive Gastric and GEJ Cancers
Although chemotherapy combinations remain standard first-line therapy for advanced or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) cancer, strategies for progressive disease have shifted to include antiangiogenic agents and immunotherapy.
Gastrointestinal oncology experts highlight what they are most excited for at the upcoming International Society of Gastrointestinal Oncology 16th Annual Gastrointestinal Oncology Conference.
Subset of <em>BRAF</em> non-V600-Mutant mCRC Is Potentially More Sensitive to Anti-EGFR Therapy
Patients with metastatic colorectal cancer who harbored BRAF non-V600, RAS-dependent mutations were more likely to respond to anti-EGFR therapy versus those with BRAF non-V600, RAS-independent mutations.
ISGIO Presents 16th Annual Gastrointestinal Oncology Conference
The International Society of Gastrointestinal Oncology, a not-for-profit global educational organization committed to gastrointestinal oncology, will host the 16th Annual Gastrointestinal Oncology Conference from Oct. 10-11, 2019 at the Hilton Crystal City in Arlington, Virginia.
Pancreatic NETs Subtypes Could Signal Risk of Recurrence
Two distinct subtypes of nonfunctional pancreatic neuroendocrine tumors could help prognosticate risk of recurrence following surgery.
Shorter Adjuvant Oxaliplatin-Based Therapy Less Effective in High-Risk Stage II CRC
Three months of adjuvant oxaliplatin-based therapy in patients with high-risk, stage II colorectal cancer was found to be inferior to 6 months of treatment.
TAS-102 Nabs Japanese Approval for Gastric Cancer
The Japanese Ministry of Health, Labour and Welfare has approved TAS-102 (trifluridine/tipiracil; Lonsurf) for the treatment of patients with unresectable advanced or recurrent gastric cancer that has progressed after chemotherapy.
Frontline Nivolumab/Ipilimumab Combo Shows Robust Activity in MSI-H/dMMR mCRC
The frontline combination of nivolumab (Opdivo) and ipilimumab (Yervoy) showed a robust and durable clinical benefit in patients with metastatic colorectal cancer.
Regorafenib/Nivolumab Combo Elicits Responses in CRC and Gastric Cancer
Shota Fukuoka, MD, PhD, discusses the results of the study evaluating regorafenib and nivolumab in patients with previously treated gastric and colorectal cancers.
ctDNA Testing Now Valuable Tool in CRC, Next Steps Underway
Pashtoon M. Kasi, MBBS, MD, MS, discusses the use of ctDNA testing throughout treatment for patients with colorectal cancer and ongoing research on liquid biopsies.
Publication Bottom Border
Border Publication